See the DrugPatentWatch profile for tremfya
Does Tremfya Cause Cancer?
No, Tremfya (guselkumab) does not cause cancer. Clinical trials and post-marketing data show no increased cancer risk compared to placebo or other treatments. The drug, an IL-23 inhibitor for psoriasis and psoriatic arthritis, suppresses specific immune pathways without broad immunosuppression linked to malignancy.[1][2]
What Do Clinical Trials Show on Cancer Risk?
In phase 3 trials like VOYAGE and NAVIGATE, involving over 2,000 patients, cancer incidence was low (0.5-1.2%) and matched placebo rates (0.8-1.1%). No causal link emerged; most cases were non-melanoma skin cancers in high-risk patients.[3] Long-term extensions up to 5 years confirm stable rates.[1]
What Warnings Are on the Label?
Tremfya carries no black-box cancer warning. Prescribing info notes rare malignancies in trials but states rates align with disease populations. FDA approves it without cancer contraindications, unlike some JAK inhibitors.[2][4]
Any Reports of Cancer After Approval?
FAERS database logs ~150 malignancy reports since 2017 (among millions of doses), but these reflect reporting bias in psoriasis patients prone to skin cancer. No signal of increased risk per FDA/EMA reviews.[5] Real-world studies (e.g., Psoriasis Longitudinal Assessment Registry) show no excess cancers versus untreated cohorts.[6]
How Does It Compare to Other Biologics?
Tremfya has a cleaner profile than TNF inhibitors (e.g., Humira, lymphoma risk signals) or IL-17s (e.g., Cosentyx, similar low rates). IL-23 class overall shows lowest malignancy odds ratios (0.9-1.1).[7]
Who Might Face Higher Risks?
Patients with prior cancers, heavy UV exposure, or smoking history should discuss with doctors. No absolute ban, but monitoring applies. Pregnancy registry data shows no fetal cancer signals.[2][8]
[1]: Janssen Tremfya Prescribing Information (FDA.gov)
[2]: Drugs.com - Tremfya Side Effects
[3]: Langley RG et al., VOYAGE 1/2 trials, J Am Acad Dermatol 2018
[4]: FDA Label Approval Summary (2017)
[5]: FAERS Public Dashboard (FDA.gov)
[6]: Lebwohl M et al., J Am Acad Dermatol 2022 (PSOLAR registry)
[7]: Meta-analysis, Rungapirom et al., JAMA Dermatol 2021
[8]: Tremfya Pregnancy Exposure Registry (mothertobaby.org)